Current management of hemophilia B: recommendations, complications and emerging issues.
Hemophilia B is a rare hereditary hemorrhagic disorder characterized by deficiency of the clotting factor IX (FIX). Hemophilia B patients experience mild-to-severe bleeding complications according to the degree of FIX defect. The mainstay of treatment of hemophilia B consists of replacement therapy and nowadays several plasma-derived and recombinant FIX products are commercially available. This article reviews the current management of hemophilia B patients analyzing the results of the most important clinical trials. In addition, it will focus on the more recent advances in the production of new FIX molecules aimed at the improvement of the clinical management of such patients.
['Franchini|Massimo|M|']
D019774:Blood Coagulation Factor Inhibitors D005164:Factor IX D015316:Genetic Therapy D006207:Half-Life D002836:Hemophilia B D006801:Humans D011092:Polyethylene Glycols D012327:RNA Virus Infections D011993:Recombinant Fusion Proteins D011994:Recombinant Proteins
hemophilia B recombinant FIX products inhibitors long-acting FIX products plasma-derived FIX concentrates